OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
414856

All Cosmos Bio-Tech Holding Corp

Agricultural ChemicalsVerified

All Cosmos Bio-Tech Holding Corp maintains a strong liquidity position with a current ratio of 4.99, indicating the company can cover its short-term liabilities nearly five times over. However, the company has negative net cash after subtracting total debt, which raises liquidity concerns. The liquidity_fpt metric shows a cash and equivalents balance of TWD 91.15 million, while long-term debt stands at TWD 381.29 million, resulting in a net cash deficit. Profitability metrics show a return on equity (ROE) of 5.58% and a return on assets (ROA) of 3.62%, which are below the industry median for Agricultural Chemicals. The company's operating margin is 10.06% (TWD 296.69 million operating income on TWD 2.95 billion revenue), and its net margin is 5.19% (TWD 153.00 million net income on TWD 2.95 billion revenue). These figures suggest the company is generating returns, but at a slower pace than the industry average. The company's revenue is concentrated in the Asia-Pacific region, with exports to Taiwan, Indonesia, Vietnam, China, Cambodia, and the Philippines. No specific revenue breakdown by geography is disclosed, but the company's primary market is Malaysia, and its products are exported to neighboring countries. The company operates through four business segments: agriculture, waste reutilization, health care and pharmaceuticals, and research and development of microbials. The company's growth trajectory is modest, with no specific revenue growth rate provided in the latest financials. The outlook for the current fiscal year is neutral, with no significant changes expected in the near term. The company's capital expenditures are negative, indicating asset disposals or reduced investment in new projects. The risk assessment indicates a low dilution risk, with no near-term pressure for share issuance. Recent events include the company's continued focus on bio-chemical fertilizers and industrial microbes, with no major regulatory or operational disruptions reported. The company's subsidiaries, including All Cosmos Industries Sdn. Bhd. and PT All Cosmos Indonesia, continue to produce over 30 different types of fertilizers for the Malaysian and Asia-Pacific markets.

30-day price · 4148-7.40 (-17.7%)
Low$33.10High$41.75Close$34.30As of21 May, 00:00 UTC
Profile
CompanyAll Cosmos Bio-Tech Holding Corp
Ticker4148.TW
SectorBasic Materials
BusinessChemicals
Industry groupChemicals
IndustryAgricultural Chemicals
AI analysis

Business. All Cosmos Bio-Tech Holding Corporation is a Malaysia-based investment holding company that operates in the agricultural chemicals industry, manufacturing and marketing bio-organic and bio-chemical fertilizers, and producing industrial microbes, fungi, and viruses for export to Asia-Pacific markets.

Classification. The company is classified under the Basic Materials economic sector, Chemicals business sector, and Agricultural Chemicals industry with a confidence level of 0.92.

All Cosmos Bio-Tech Holding Corp maintains a strong liquidity position with a current ratio of 4.99, indicating the company can cover its short-term liabilities nearly five times over. However, the company has negative net cash after subtracting total debt, which raises liquidity concerns. The liquidity_fpt metric shows a cash and equivalents balance of TWD 91.15 million, while long-term debt stands at TWD 381.29 million, resulting in a net cash deficit. Profitability metrics show a return on equity (ROE) of 5.58% and a return on assets (ROA) of 3.62%, which are below the industry median for Agricultural Chemicals. The company's operating margin is 10.06% (TWD 296.69 million operating income on TWD 2.95 billion revenue), and its net margin is 5.19% (TWD 153.00 million net income on TWD 2.95 billion revenue). These figures suggest the company is generating returns, but at a slower pace than the industry average. The company's revenue is concentrated in the Asia-Pacific region, with exports to Taiwan, Indonesia, Vietnam, China, Cambodia, and the Philippines. No specific revenue breakdown by geography is disclosed, but the company's primary market is Malaysia, and its products are exported to neighboring countries. The company operates through four business segments: agriculture, waste reutilization, health care and pharmaceuticals, and research and development of microbials. The company's growth trajectory is modest, with no specific revenue growth rate provided in the latest financials. The outlook for the current fiscal year is neutral, with no significant changes expected in the near term. The company's capital expenditures are negative, indicating asset disposals or reduced investment in new projects. The risk assessment indicates a low dilution risk, with no near-term pressure for share issuance. Recent events include the company's continued focus on bio-chemical fertilizers and industrial microbes, with no major regulatory or operational disruptions reported. The company's subsidiaries, including All Cosmos Industries Sdn. Bhd. and PT All Cosmos Indonesia, continue to produce over 30 different types of fertilizers for the Malaysian and Asia-Pacific markets.
Key takeaways
  • The company has a strong current ratio of 4.99, but negative net cash after subtracting total debt raises liquidity concerns.
  • ROE and ROA are below the industry median, indicating lower profitability relative to peers.
  • Revenue is concentrated in the Asia-Pacific region, with no detailed geographic breakdown provided.
  • Growth is modest, with no significant changes expected in the near term.
  • The company has low dilution risk, with no near-term pressure for share issuance.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyTWD
Revenue$2.95B
Gross profit$829.5M
Operating income$296.7M
Net income$153.0M
R&D
SG&A
D&A
SBC
Operating cash flow$253.0M
CapEx-$43.9M
Free cash flow$196.3M
Total assets$4.22B
Total liabilities$1.48B
Total equity$2.74B
Cash & equivalents$91.1M
Long-term debt$381.3M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0$2.95B$296.7M$153.0M$196.3M
FY-1$2.46B$160.9M$128.6M$22.2M
FY-2$2.83B$189.9M$139.4M-$85.1M
FY-3$3.70B$667.0M$368.2M$348.1M
FY-4$2.20B$273.2M$198.1M$117.4M
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0$4.22B$2.74B$91.1M
FY-1$3.67B$2.52B$95.9M
FY-2$3.67B$2.25B$379.2M
FY-3$4.11B$2.37B$374.7M
FY-4$2.97B$1.99B$143.0M
PeriodOCFCapExFCFSBC
FY0$253.0M-$43.9M$196.3M
FY-1$54.2M-$142.2M$22.2M
FY-2$959.2M-$163.4M-$85.1M
FY-3$43.8M-$60.9M$348.1M
FY-4-$67.6M-$103.8M$117.4M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0$831.8M$77.2M$35.1M$69.6M
FQ-1$829.8M$95.9M$68.8M$89.1M
FQ-2$739.5M$84.7M$36.1M$53.6M
FQ-3$547.9M$39.0M$13.1M$16.0M
FQ-4$710.4M$42.8M$20.0M$33.9M
FQ-5$746.3M$89.1M$72.1M$72.3M
FQ-6$478.4M$5.3M$8.0M-$2.0M
FQ-7$523.5M$23.8M$28.5M-$17.9M
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0$4.22B$2.74B$91.1M
FQ-1$3.88B$2.55B$61.0M
FQ-2$3.72B$2.39B$152.6M
FQ-3$3.71B$2.54B$122.4M
FQ-4$3.67B$2.52B$95.9M
FQ-5$3.84B$2.61B$70.0M
FQ-6$3.75B$2.28B$263.2M
FQ-7$3.70B$2.24B$371.6M
PeriodOCFCapExFCFSBC
FQ0$253.0M-$43.9M$69.6M
FQ-1-$14.3M-$38.1M$89.1M
FQ-2-$213.9M-$33.6M$53.6M
FQ-3$55.4M-$23.1M$16.0M
FQ-4$54.2M-$142.2M$33.9M
FQ-5-$44.0M-$130.2M$72.3M
FQ-6$32.5M-$103.3M-$2.0M
FQ-7$64.2M-$71.2M-$17.9M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$2.74B
Net cash-$290.1M
Current ratio5.0
Debt/Equity0.1
ROA3.6%
ROE5.6%
Cash conversion1.6%
CapEx/Revenue-1.5%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Chemicals · cohort 11 companies
Metric4148Activity
Op margin10.1%0.4% medp25 -8.0% · p75 16.0%above median
Net margin5.2%2.3% medp25 -11.6% · p75 11.8%above median
Gross margin28.1%20.8% medp25 14.9% · p75 24.0%top quartile
R&D / revenue1.1% medp25 0.5% · p75 1.3%
CapEx / revenue-1.5%6.2% medp25 5.4% · p75 10.2%bottom quartile
Debt / equity14.0%59.0% medp25 54.9% · p75 72.9%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 08:00 UTC#5cacc39c
Market quoteclose TWD 36.80 · shares 0.07B diluted
no public URL
2026-05-04 01:03 UTC#b8704886
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 08:03 UTCJob: d08f2752